Utilising murine syngeneic model systems in I/O drug discovery: broad applications and guidance on model selection and data interpretation
Ying Jin, Annie An, Lan Zhang, Haochen Wu, Binchen Mao, Sheng Guo, Qian Shi, Henry Q. Li and WenQing Yang
Syngeneic models are a valuable tool for evaluating the anti-tumour effects of a variety of cancer immunotherapies. To optimise model use, and truly understand the interplay between immunomodulation and anti-tumour phenotype, in depth syngeneic characterisation is required.
We’ve characterised the syngeneic models used in our MuScreen™ in vivo screening platform. This immunoprofiling includes capturing the dynamic changes of immune cell presence and infiltration within different compartments of tumour-bearing mice, after treatment with checkpoint inhibitors.
The resulting datasets reveal changes in immune profile relative to anti-tumour response, and can help guide strategic decisions on preclinical model, as well as combinatorial drug selection.
Read this Poster to Discover:
- That comprehensive characterisation studies show variable basal level immune cell tumour infiltration for each syngeneic model, as well as high variation of immunophenotypic changes in response to PD-1 blockade for individual mice
- How variable levels of immune cell infiltration are observed in each of the syngeneic models, which could guide model selection based on MOA or proposed target immune cells
- That a trend of meaningful immunomodulatory changes are observed in models with robust tumour growth inhibition following aPD-1 treatment, but no clear pattern of immunoprofiling changes are seen in less responsive or resistant models